On March 4, 2024 DotBio reported its lead candidate, DB007, has begun animal efficacy studies (Press release, DotBio, MAR 4, 2024, View Source [SID1234646740]). DB007 is a tri-specific antibody designed to reinvigorate exhausted immune cells to fight cancer more effectively. This study was conducted in the Agency for Science, Technology and Research (A*STAR).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!